Steven Hirschfeld

List of Publications by Year
in descending order

70 papers	2,912 citations	257357 24 h-index	168321 53 g-index
73 all docs	73 docs citations	73 times ranked	4055 citing authors

#	Article	IF	Citations
1	Challenges in clinical trials for children and young people. Archives of Disease in Childhood, 2021, 106, 321-325.	1.0	21
2	Health Measurement Modelâ€"Bringing a Life Course Perspective to Health Measurement: The PRISM Model. Frontiers in Pediatrics, 2021, 9, 605932.	0.9	3
3	Prerequisites to support high-quality clinical trials in children and young people. Archives of Disease in Childhood, 2021, 106, 423-428.	1.0	4
4	Principles of Researching Health Disparities in Longitudinal Cohort Studies Enrolling Children. Frontiers in Pediatrics, 2021, 9, 627298.	0.9	3
5	What Could the Future of Safety Monitoring Look Like?. Therapeutic Innovation and Regulatory Science, 2019, 53, 590-600.	0.8	3
6	Weight estimation among multi-racial/ethnic infants and children aged 0â€"5Â·9 years in the USA: simple tools for a critical measure. Public Health Nutrition, 2019, 22, 147-156.	1.1	2
7	Assessment of a shortened informed consent form for pediatric research: a pilot study. Pediatric Research, 2018, 84, 516-519.	1.1	5
8	Introduction and Goals for the National Childrenâ€™s Study. Frontiers in Pediatrics, 2018, 5, 240.	0.9	7
9	Immunization in pregnancy clinical research in low- and middle-income countries â€“ Study design, regulatory and safety considerations. Vaccine, 2017, 35, 6575-6581.	1.7	22
10	Development of a Pediatric Adverse Events Terminology. Pediatrics, 2017, 139, .	1.0	20
11	Frameworks for Evaluating Medicines in Children. Clinical Therapeutics, 2017, 39, 1949-1958.	1.1	5
12	Global alignment of immunization safety assessment in pregnancy â€“ The GAIA project. Vaccine, 2016, 34, 5993-5997.	1.7	72
13	Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. Vaccine, 2016, 34, 5998-6006.	1.7	42
14	Predictive Models for Characterizing Disparities in Exclusive Breastfeeding Performance in a Multi-ethnic Population in the US. Maternal and Child Health Journal, 2016, 20, 398-407.	0.7	2
15	Improving the value of clinical research through the use of Common Data Elements. Clinical Trials, 2016, 13, 671-676.	0.7	93
16	Reframing clinical trial design and intervention development.. Journal of Clinical Oncology, 2016, 34, e14044-e14044.	0.8	0
17	Sponsors meet scientists to speed pediatric medicines development. Science Translational Medicine, 2015, 7, 279fs11.	5.8	3
18	A child is a child is a child? Paediatric terminology in a health context. Developmental Medicine and Child Neurology, 2015, 57, 985-985.	1.1	1

#	Article	IF	Citations
19	Longer breastfeeding duration reduces the positive relationships among gestational weight gain, birth weight and childhood anthropometrics. Journal of Epidemiology and Community Health, 2015, 69, 632-638.	2.0	18
20	Harmonizing Biomarker Measurements in Longitudinal Studies of Childrenâ€™s Health and the Environment. Biomonitoring, 2014, 1, .	1.0	9
21	Meeting the Demand for Pediatric Clinical Trials. Science Translational Medicine, 2014, 6, 227fs11.	5.8	23
22	Paediatric drug development: The impact of evolving regulations. Advanced Drug Delivery Reviews, 2014, 73, 2-13.	6.6	124
23	Arm Span and Ulnar Length Are Reliable and Accurate Estimates of Recumbent Length and Height in a Multiethnic Population of Infants and Children under 6 Years of Age. Journal of Nutrition, 2014, 144, 1480-1487.	1.3	19
24	Building a Common Pediatric Research Terminology for Accelerating Child Health Research. Pediatrics, 2014, 133, 516-525.	1.0	35
25	Optimized DNA extraction from neonatal dried blood spots: application in methylome profiling. BMC Biotechnology, 2014, 14, 60.	1.7	41
26	A Federated Model of IRB Review for Multisite Studies: A Report on the National Children's Study Federated IRB Initiative. IRB: Ethics & Human Research, 2014, 36, 1-6.	0.8	26
27	The National Children's Study â€" A Proposed Plan. New England Journal of Medicine, 2013, 369, 1873-1875.	13.9	22
28	New Models for Large Prospective Studies: Is There a Better Way?. American Journal of Epidemiology, 2012, 175, 859-866.	1.6	110
29	The National Childrenâ€™s Study: An Opportunity for Medical Toxicology. Journal of Medical Toxicology, 2012, 8, 160-165.	0.8	16
30	HIV-1 infected monozygotic twins: a tale of two outcomes. BMC Evolutionary Biology, 2011, 11, 62.	3.2	10
31	National Children's Study: Update in 2010. Mount Sinai Journal of Medicine, 2011, 78, 119-125.	1.9	20
32	Pediatric Regulatory Initiatives. Handbook of Experimental Pharmacology, 2011, 205, 245-268.	0.9	37
33	Current Status of the National Children's Study. Epidemiology, 2010, 21, 605-606.	1.2	5
34	Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?. Journal of Clinical Oncology, 2009, 27, 4398-4405.	0.8	81
35	Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy. Cytotherapy, 2008, 10, 312-316.	0.3	11
36	Resource expectations for pediatric studies: Correlation of study type and patient number for FDA labeling. Journal of Clinical Oncology, 2008, 26, 6632-6632.	0.8	2

#	Article	IF	Citations
37	Progression-free survival as an end-point in clinical trials of biotherapeutic agents. European Journal of Cancer, Supplement, 2007, 5, 23-28.	2.2	10
38	The Role of the FDA in Cancer Clinical Trials. , 2007, 132, 51-109.		1
39	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266.	2.0	445
40	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 491-505.	2.0	165
41	Pediatric Patients and Drug Safety. Journal of Pediatric Hematology/Oncology, 2005, 27, 122-124.	0.3	4
42	A survey of phase I study designs of cellular, gene therapy and antigenic products for cancer at the US Food & Drug Administration. Journal of Clinical Oncology, 2005, 23, 6035-6035.	0.8	0
43	Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials. Journal of Antimicrobial Chemotherapy, 2004, 54, 701-703.	1.3	7
44	FDA Drug Approval Summaries: Oxaliplatin. Oncologist, 2004, 9, 8-12.	1.9	150
45	The pediatric research equity act and oncology. Pediatric Blood and Cancer, 2004, 43, 99-102.	0.8	3
46	Threshold of Credibility: A New Approach to Product Development for Metastatic Melanoma Therapy. Journal of Immunotherapy, 2004, 27, S55.	1.2	0
47	Threshold of Credibility: New Approach to Licensing Acute Leukemia Therapy.. Blood, 2004, 104, 3128-3128.	0.6	1
48	Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives. Journal of Clinical Oncology, 2003, 21, 1066-1073.	0.8	205
49	Oncology drug development: United States Food and Drug Administration perspective. Critical Reviews in Oncology/Hematology, 2002, 42, 137-143.	2.0	30
50	DEVELOPMENTAL THERAPEUTICS IN CHILDHOOD CANCER. Hematology/Oncology Clinics of North America, 2001, 15, 631-655.	0.9	9
51	The FDA and The Lancet : an exchange. Lancet, The, 2001, 358, 415.	6.3	3
52	Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene. Oncologist, 2001, 6, 4-11.	1.9	86
53	Pediatric Oncology: Regulatory Initiatives. Oncologist, 2000, 5, 441-444.	1.9	12
54	Working Group Session Report: Cancer. Journal of Nutrition, 1999, 129, 306S-307S.	1.3	3

#	Article	IF	Citations
55	Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemotherapy and Pharmacology, 1999, 44, 417-421.	1.1	49
56	Pain as a Complication of HIV Disease. AIDS Patient Care and STDs, 1998, 12, 91-108.	1.1	13
57	Thyroid abnormalities in children infected with human immunodeficiency virus. Journal of Pediatrics, 1996, 128, 70-74.	0.9	34
58	Dysregulation of Growth and Development in HIV-Infected Children. Journal of Nutrition, 1996, 126, 2641S-2650S.	1.3	13
59	Dealing with Death: Visions of Those Who Left Too Soon. American Journal of Nursing, 1996, 96, 57.	0.2	0
60	Use of Human Recombinant Growth Hormone and Human Recombinant Insulin-Like Growth Factor-I in Patients with Human Immunodeficiency Virus Infection. Hormone Research, 1996, 46, 215-221.	1.8	24
61	Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways.. Molecular and Cellular Biology, 1993, 13, 2258-2268.	1.1	79
62	Inhibition of Estrogen-Responsive Gene Activation by the Retinoid X Receptor Î²: Evidence for Multiple Inhibitory Pathways. Molecular and Cellular Biology, 1993, 13, 2258-2268.	1.1	23
63	H-2RIIBP expressed from a baculovirus vector binds to multiple hormone response elements.. Molecular Endocrinology, 1992, 6, 219-230.	3.7	32
64	Selected issues in human immunodeficiency virus infection in adolescents. Current Opinion in Pediatrics, 1992, 4, 599-606.	1.0	2
65	Expression of major histocompatibility complex (MHC) class I genes in astrocytes correlates with the presence of nuclear factors that bind to constitutive and inducible enahcers. Journal of Neuroimmunology, 1992, 41, 35-42.	1.1	16
66	A constitutive damage-specific DNA-binding protein is synthesized at higher levels in UV-irradiated primate cells.. Molecular and Cellular Biology, 1990, 10, 2041-2048.	1.1	95
67	Cloned Trans-Acting Factors that Bind to the Regulatory Elements of the Major Histocompatibility Complex Class I Gene. , 1990, , 125-132.		1
68	Developmental and tissue-specific expression of nuclear proteins that bind the regulatory element of the major histocompatibility complex class I gene.. Journal of Experimental Medicine, 1989, 169, 1309-1321.	4.2	93
69	H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8289-8293.	3.3	298
70	History of Children and the Development of Regulations at the FDA. , 0, , 6-15.		4